Relmada Therapeutics Inc. (RLMD) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Relmada Therapeutics Inc. (NASDAQ: RLMD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $3.58 (+4.07% 1D, market cap $366.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RLMD carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SPRY (ARS Pharmaceuticals Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $364.0M) and EBS (Emergent BioSolutions Inc.) posts a D+ grade (52/100 RQD, P/E 7.0x, ROIC 8.9%, cap $370.2M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).
Per RLMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001553643), Relmada Therapeutics Inc. generated $0 in revenue, $0 in net income, and -$45.8M in free cash flow against $94.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While RLMD currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.82) and Max Pain ($3.76) forces dealer call-delta covering toward $8.40.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Relmada Therapeutics Inc. (RLMD) surged +4.07% to $3.58, trading at 24% of its 52-week range ($2.15 – $8). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RLMD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RLMD. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Relmada Therapeutics Inc. (RLMD) ranks #846 by composite RQD confidence (30/100, grade E) and #494 by equity capitalization ($366.9M). Within this direct 5-issuer industry benchmark cohort, EBS leads on earnings valuation at 7.0x trailing P/E, while EBS leads on capital efficiency and profitability with 8.9% ROIC and 56.1% gross margin. EBS currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with RLMD at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RLMD
ACTIVE
Relmada Therapeutics Inc. | E | 30/100 | — | — | -35.0% | +4.07% | $366.9M | Benchmark Subject |
| SPRY ARS Pharmaceuticals Inc. | E | 20/100 | — | — | -35.0% | -7.65% | $364.0M | /spry-vs-rlmd → |
| EBS Emergent BioSolutions Inc. | D+ | 52/100 | 7.0x | 56.1% | 8.9% | -5.68% | $370.2M | /ebs-vs-rlmd → |
| CYPH Cypherpunk Technologies Inc. | D | 45/100 | 71.3x | — | -23.3% | -9.97% | $356.7M | /cyph-vs-rlmd → |
| GALT Galectin Therapeutics Inc. | D- | 39/100 | — | — | -35.0% | -5.68% | $355.8M | /galt-vs-rlmd → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Relmada Therapeutics Inc. (RLMD) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $0, operating cash flow of -$45.8M, and free cash flow of -$45.8M (+11.5% YoY). On the balance sheet, RLMD closed FY2025 with $94.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | -$45.8M | -$45.8M | $94.0M | — |
| FY2024 (FY) | 2024-12-31 | $0 | $0 | -$51.8M | -$51.8M | $45.8M | — |
As of 2026-11-02, Relmada Therapeutics Inc. (NASDAQ: RLMD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $3.58 (+4.07% 1D, market cap $366.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RLMD carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SPRY (ARS Pharmaceuticals Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $364.0M) and EBS (Emergent BioSolutions Inc.) posts a D+ grade (52/100 RQD, P/E 7.0x, ROIC 8.9%, cap $370.2M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).
Per RLMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001553643), Relmada Therapeutics Inc. generated $0 in revenue, $0 in net income, and -$45.8M in free cash flow against $94.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
RLMD last traded at $3.58 (+4.07% on volume of 1,413,760 shares), positioning the stock -6.28% below its 50-day simple moving average ($3.82) and -33.21% below its 200-day simple moving average ($5.36). Across its 52-week range of $2.15 to $8.00, RLMD sits at the 24.4% percentile with a 14-day RSI of 47.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.13 to $4.03).
Why RLMD Stock surged +4.07% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, RLMD scores 30 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 6/20 (ROIC of -35%; FCF yield of -12.48%), Whale 13F Flow at 5/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 6/20 (Beta of 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z of 2.5; Piotroski F of 1/9; Debt/Equity of 0.5). Taken together, the low scores on cash generation, insider conviction, and institutional flow mean the rating does not identify an upside driver strong enough to offset the negative free cash flow profile. For a prospective investor, the practical implication is that any upside thesis would have to rest on a future event outside the reported cash engine, such as a pipeline milestone, rather than on current earnings power. The Forensic Balance Sheet pillar, the strongest of the five at 10/20, still carries a low Piotroski F-Score of 1/9, which signals weak financial health indicators.
Relmada Therapeutics Inc. is a NASDAQ-listed issuer classified in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company has a market capitalization of $0.4B. The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M for both FY 2025 and FY 2024 in the SEC financials, indicating no revenue recognition in the reported periods.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-59.1M | $0.0M | N/A | $-45.8M | $3.5M | N/A |
| FY 2024 | $0.0M | $-83.9M | $0.0M | N/A | $-51.8M | $3.9M | N/A |
Per the SEC financials, operating losses were $-59.1M in FY 2025 and $-83.9M in FY 2024, and free cash flow was negative in both periods. Per the market data, gross, operating, and net margins are each reported as 0%, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, both per the Roarable RQD rating. Per the same rating, Debt/Equity is 0.5, while the debt line in the SEC financials is reported as N/A.
The news feed contains six items, all tagged to RLMD and all carrying a YELLOW light and "MARKET WIRE" impact label. The headlines reference a Seasonal Returns Chart, an options chain, a Q2 2026 earnings call transcript, a Q3'26 earnings preview listing a revenue estimate of 0 USD, a piece on Allarity Therapeutics (ALLR) described as a "buy the bottom" candidate, and a general U.S. stock listing. The summaries are generic and do not disclose trial results, regulatory actions, or deal terms. Per the Butterfly Supply-Chain Graph, a proprietary LIQUIDITY_TAILWIND signal with a severity score of 94 is marked BULLISH, with a macro tailwind score of 96/100 and a 4.19 z-score across FRED Fed Assets, US Treasury TGA, and ON RRP feeds. The same signal reports true net liquidity of $5,746B, a 4-week rate of change of -0.64%, and a 2 bps delta in high-yield OAS. It also cites a high 4.02x beta elasticity to net liquidity and an inverse Pearson correlation of -0.16. This signal is macro in nature and is not tied to a company-specific catalyst.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE and there are no butterfly links, so no upstream or downstream dependencies are mapped in the source data. The only cross-market linkage is the macro liquidity signal, which implies the stock's sensitivity to broad liquidity conditions rather than to any specific supplier or customer. Because the graph shows a high beta elasticity to net liquidity, a prospective investor should note that liquidity-driven moves could amplify price changes in either direction. The news feed's reference to Allarity Therapeutics (ALLR) is the only named peer, and the source data does not establish a supply-chain or competitive relationship between the two companies.
Real-time company headlines, analyst actions, and sector developments for Relmada Therapeutics Inc. (RLMD) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Welcome to the RLMD (Relmada Therapeutics Inc.) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on RLMD, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Relmada Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on RLMD, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.44 (52-wk range $2.15 - $8.00), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).